Emirates News Agency on MSN
UAE approves gene replacement therapy for new age group in spinal muscular atrophy patients
The Emirates Drug Establishment (EDE) has announced the approval of Itvisma (onasemnogene abeparvovec), a gene therapy that ...
Edex Live on MSN
UAE approves gene replacement therapy for wider SMA age group
The Emirates Drug Establishment (EDE) has announced the approval of Itvisma (onasemnogene abeparvovec), a gene therapy that uses an adeno-associated viral vector to treat spinal muscular atrophy (SMA) ...
NeuExcell Therapeutics announced encouraging clinical results of NXL-004, the world’s first in situ conversion gene therapy ...
The gene therapies for cardiomyopathies market is poised for strong growth as advancements in genomic medicine accelerate the development of ...
Dubai, UAE: The Emirates Drug Establishment (EDE) has announced the approval of Itvisma™ (onasemnogene abeparvovec), a gene therapy that uses an adeno-associated viral vector to treat spinal muscular ...
Minaris will move its center for viral vector innovation to occupy space within CGT Catapult’s collaborator laboratories in London and will work with CGT Catapult on the further development of ...
D Molecular Therapeutics, Inc. (NASDAQ:FDMT) is among the Best Get Rich Fast Stocks to Buy Right Now. As of December 24, 4D ...
Khaleej Times on MSN
UAE approves gene therapy for new age group in spinal muscular atrophy patients
The Emirates Drug Establishment (EDE) has announced the approval of Itvisma (onasemnogene abeparvovec), a gene therapy that ...
X-linked retinoschisis gene replacement therapy, aiming to improve retinal architecture and visual function in young male ...
Hemophilia B, a genetic bleeding disorder caused by deficient factor IX activity, has traditionally required lifelong prophylactic intravenous infusions. Etranacogene dezaparvovec, a gene therapy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback